Abstract
Introduction
West Nile Virus (WNV) is one of the most widely distributed arboviruses in the world, and a pathogen of public health significance in both humans and animals [1] . This mosquito-borne virus has been classified in the genus Flavivirus within the family Flaviviridae [2] . In nature, WNV is maintained in a zoonotic transmission cycle between birds and mosquitos, principally the Culex species. Susceptibility to WNV infection has also been indicated for many other vertebrate hosts including mammals, birds, reptiles, and amphibians [3] . Equines and humans are incidental "dead-end" hosts who do not play a role in the transmission cycle of the virus. However, equines and humans may manifest sever disease or death as a consequence of infection [4] . Since the first discovery of the virus in 1937 in the West Nile district of Uganda [5] , it has undergone a substantial geographical migration, and spread around the globe. Infection with WNV was first identified in an EMRO country (Sudan) in the 1940s. Since then, infection with the virus has been reported in Egypt (1950s) , Iran (1970s) , and subsequently in several other countries across the region [6] . The prevention and control efforts substantially rely on effective surveillance of the infection in birds, vectors, animals, and humans. Despite several studies on different aspects of WNV epidemiology in the EMRO region, there are still many unknowns about the circulation of the virus and the driving factors of outbreaks [6, 7] . Understanding the epidemiology of WNV in the EMRO faces a number of challenges including inadequate knowledge of physicians about the nature of the disease, misdiagnosis of other common infectious diseases due to similarity in clinical presentations, poor diagnostic infrastructures and the absence of confirmatory assays for serological tests, and lack of a comprehensive and progressive monitoring and surveillance system in majority of countries. The latter has resulted in a gap in knowledge regading the prevalence of WNV infection in the EMRO region. Therefore, we designed a systematic review to provide a clear and comprehensive presentation of the virus prevalence distribution among human and animal populations as well as infection rate in vectors of the region, based on available data.
Methods

Data sources and search strategy
Articles were screened and selected according to the PRISMA criteria [8] . The PRISMA checklist completed for this review is presented in S1 File. We made an electronic literature search through Web of Science, Scopus, PubMed, Google Scholar, and Index Medicus for the Eastern Mediterranean region database (IMEMR) using different combinations of the following keywords 'West Nile virus, West Nile Fever, WNV' and the name of the EMRO countries as: Afghanistan, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, United Arab Emirates, and Yemen (S2 File). All databases were searched for English-language original articles published from database inception to January 30, 2018 . Choosing multiple sources for article search we aimed to enhance our sensitivity in finding relevant articles. To find citations that were not indexed in our target databases, we reviewed the reference lists of relevant articles.
Review selection
Studies identified through electronic and manual searches were listed in EndNote software (EndNote X7, Thomson Reuters). After exclusion of duplicate citations, two authors (MF, FS) independently reviewed titles and abstracts according to the research question. Relevant studies were obtained in full, and assessed for eligibility and risk of bias as described below. All original articles from peer-reviewed scientific journals with a cross-sectional or survey design that estimated the prevalence of WNV infection in humans, animals, or infection rate in vectors were potentially eligible for inclusion in this review. Relevant studies whose abstract was available but their full-text was not (even after contacting the authors via e-mail), were kept in this review in order to present all available data. Studies from outside of the EMRO region were excluded. Any disagreements between the review team were resolved through discussion.
Risk of bias assessment
The risk of bias in primary studies was assessed following the Cochrane approach [9] . We also considered individual studies' sample size (precision) as a criterion to assess risk of bias, as proposed by Humphre, et al. [10] . Therefore, we evaluated each WNV prevalence study in three domains: 1) sampling method, 2) response level (the proportion of subjects who accept to participate in the study), and 3) type of assay used for the detection of WNV. Each study was considered to have a low risk of bias if: 1) it used probability-base/random sampling methods, 2) maintained participants' response level at �80% [11, 12] , or 3) it employed viral neutralization testing (VNT) for a prevalence study on the general population or used biological tests including viral genome detection and virus isolation from infected individuals. Studies were classified as having unclear risk of bias for a given domain if they did not provide information for that specific domain. Use of probabilistic sampling methods was only evaluated for studies on the general population, because acute infection studies included individuals attending to healthcare facilities. For studies that were conducted on blood samples collected and stored from blood donors, response rate criteria were not evaluated. Studies on human subjects were considered to have high precision if their sample sizes were � 100 [13] . Moreover, in the studies on WNV vectors, minimum infection rates (MIR), that were calculated for samples of � 1000 specimens, were considered as a reliable representation of the true infection rate in the vector population [14, 15] .
Data extraction
Data was extracted from the selected studies using a researcher-made and piloted data extraction form in excel. For studies on human and animal subjects we extracted data on: first author, year of publication, year of implementation, country, city/governorate, sample size, participants' age and sex (for human subjects only), animal species (for studies on animals), assay type, and estimated assay-based WNV prevalence. For studies on vector populations, further data was extracted including vector species, number of species (vectors) tested, collection methods, number and size of the pools as well as the number of positive pools for each species. WNV minimum infection rate (MIR) for each species was calculated by dividing the number of positive pools by the total number of specimens tested for that specific species and multiplied by 1000. When data was available, assay-specific MIRs were calculated and reported.
Results
Search results
Database search resulted in 3298 records. After removal of duplicates, we initially screened the title and abstract of 2667 records, 2488 of which were excluded as they were irrelevant to this review. The remaining 179 papers were reviewed in full, of which 77 eligible reports on the prevalence/MIR of WNV covering 17 countries in the EMRO region were included in this systematic review. We identified two relevant citations by reviewing the reference list of these relevant studies [16, 17] . Fig 1 shows the literature search process. The full-text of five studies could not be obtained even after contacting the authors [18] [19] [20] [21] [22] . These studies were kept in this review to present all available data to the readers. All included studies on WNV entailed 27899 individuals (24460 general populations and 3439 patients), 10309 animals, and 184242 vector species.
Risk of bias assessment results
A summary of the risk of bias assessment results is shown in Table 1 . In brief, most human studies (28 out of 35) contained sample sizes of �100 participants, yielding a high precision in the reported prevalence measure. Thirty out of thirty-five studies on the general population reported their sampling strategy, fourteen of which utilized some forms of random sampling, and hence, had low risk of bias at this domain. In most studies on the general population (24 out of 35), risk of bias assessment was affected by unclear reporting in the 'response rate' domain. Six studies were performed on volunteers or on blood specimens stored in national reference laboratories or blood transfusion centers, and hence, were not subjected to risk of bias assessment in the 'response rate' domain. Viral neutralization test was performed in 40.0% and 13.3% of prevalence studies on the general and patient populations, respectively, which entails a low risk of bias for the assays used. Four citations included data on more than one subject categories (i.e., humans, animal species, and vectors). 
WNV prevalence among the general and patient populations of the EMRO region
A total of 50 human prevalence studies for WNV were identified, 35 of which estimated the seroprevalence in the general population. Furthermore, and 15 of them investigated the presence of WNV antibody or genetic material in patients suspected with WNV infection. Human studies covered 14 of 22 countries of the EMRO region, and were published from 1942 to 2017. The highest number of human studies were reported from Egypt (n = 10), Iran (n = 8), and Pakistan (n = 9), most of which targeted the general population. ELISAs were the most commonly used diagnostic method for the general and patient populations. Table 2 presents detailed data for these studies. The geographic distribution of human prevalence studies is also illustrated in Fig 2A and 2B .
Regarding the general population, WNV antibodies were detected in 11 countries including Djibouti (n = 2, 0.3-60%), Egypt (n = 7, 1-61%), Iran (n = 6, 0-30%), Iraq (n = 1, 11.6-15.1%), Jordan (n = 1, 8%), Lebanon (n = 2, 0-1%), Libya (n = 1, 2.3%), Morocco (n = 3, 0-18.8%), Pakistan (n = 5, 0.2-65%), Sudan (n = 5, 2.2-47%), and Tunisia (n = 1, 4.3-31.1%). Since 2010, seroprevalence of WNV among the general population has been investigated in Djibouti, Egypt, Iran, Iraq, Libya, Morocco, and Sudan among which the lowest and highest median prevalence was found in Iran (median prevalence = 1.4, range: 0-18%; total SS = 1322; 2010-2012), and Egypt (median prevalence = 55%; total SS = 160, 2013-2014), respectively ( Table 2 ).
In addition, the presence of WNV antibody or genetic material in patients was investigated in 15 human prevalence studies. In this regard, seven studies assessed WNV IgM, five of which detected the antibodies in patients' sera. These studies were from Afghanistan (n = 1, 0.5%), Pakistan (n = 1, 6.6%), Sudan (n = 2, 0.3-87.5%), and Yemen (n = 1, 14.3%). Four studies [56, 59, 63, 64] used both serological and molecular assays to detect WNV IgM as well as WNV RNA in patients' sera ( Table 2) . � On blood specimens stored in the blood transfusion center �� On volunteers ‡ Studies were classified as having "Unclear" risk of bias for a given domain if they did not provide information for that specific domain. These studies were categorized as "Unclear" risk of bias. ¥ Use of probabilistic sampling methods was only evaluated for studies on the general population, because acute infection studies included individuals attending to healthcare facilities. So, risk of bias assessment for the "sampling" domain, was "Not Applicable" (NA) for patients. Tables 2 and 3 . Countries with no qualified study on human or animal populations are colored in gray. ×2: Where more than one study/sampling effort have been done on a particular species in the same geographic area. UAE: United Arab Emirates. � MIR was calculated by dividing the number of positive pools by the total number of specimens tested and multiplied by 1000. Where the number of tested specimens is below 1000, the MIR may not accurately represent the true infection rate in the population, and should be interpreted with caution. § Mosquitoes were sorted to species, pooled, and processed for virus isolation both by intracerebral inoculation into suckling mice and by inoculation into cell culture. A total of 33 virus isolates was made from 36,024 mosquitoes. Virus identification was performed using indirect fluorescent antibody testing. ‡
The data for this studiy is driven from articles' abstract, as their full-text could not be obtained. 
WNV prevalence in wild and domestic animals in the EMRO region
A total of 22 studies investigated the WNV seroprevalence in animals (Fig 2A and 2B) . WNV antibodies were detected in 10 countries, including, Djibouti (n = 1), Iran (n = 4), Jordan (n = 1), Morocco (n = 4), Pakistan (n = 2), Palestine (n = 1), Qatar (n = 2), Saudi Arabia (n = 1), Tunisia (n = 5) and the United Arab Emirates (UAE; n = 1). In these studies, serological evidence of WNV infection was detected in a wide range of domestic and wild animals, including Buffalos (Pakistan, total SS = 33, prevalence = 15.1%), Camels (Morocco, total SS = 2775, prevalence = 8-23%; Palestine, total SS = 35, Prevalence = 40%; Tunisia, total SS = 120, Prevalence = 0-25.8%), Cows (Pakistan, total SS = 45, prevalence = 2.2%), Goats and sheep (Pakistan, total SS = 94, prevalence = 23.9%; Palestine, total SS = 95, prevalence = 14.7%), Dogs (Djibouti, total SS = 91, prevalence = 56.5%; Morocco, total SS = 231, prevalence = 54-96%), Ruminants (Djibouti, total SS = 11, prevalence = 25.3%), Equids (Iran, total SS = 1839, prevalence = 0.8-70.3%; Jordan, total SS = 253, prevalence = 24.9%; Morocco, total SS = 1189, prevalence = 25-100%; Pakistan, total SS = 449, prevalence = 65%; Palestine, total SS = 585, prevalence = 75%; Qatar, total SS = 421, prevalence: 0-27%; Saudi Arabia, total SS = 63, prevalence = 33.5%; Tunisia, total SS = 1473, prevalence = 28.0-45.2%; the UAE, total SS = 750, prevalence = 5.4-28.6%), and different types of wild and domestic birds (Iran, total SS = 519, prevalence = 15%; Morocco, total SS = 346, prevalence = 3.5%; Tunisia, total SS = 434, prevalence = 0.7-23%). Table 3 provides further details on these studies.
Infection rate of vectors with WNV in the EMRO region
Nine studies investigated arthropods in order to analyze the WNV infection rate among vectors. These reports were from Djibouti (n = 2), Egypt (n = 2), Iran (n = 2), Lebanon (n = 1), Pakistan (n = 1), and Tunisia (n = 1 Table 4 and Fig 3. 
Discussion
Seroprevalence of WNV has been investigated in 14 of 22 countries in the EMRO region. Since 1942, WNV antibodies have been detected in the general population in 11 countries with available data, including: Djibouti, Egypt, Iran, Iraq, Jordan, Lebanon, Libya, Morocco, Pakistan, Sudan, and Tunisia. Our results also suggested that the overall seroprevalence of WNV has been lower in reports from more recent years (since 2010) compared to reports compiled between 1942 and 2009. Although the presence of WNV infection remains unknown in countries without data in the EMRO region (n = 14), it can be implied that the virus may probably circulate within these countries as well. Existing evidence suggests cross-country dispersion of a number of viruses such as human immunodeficiency virus (HIV) [91] and hepatitis B virus (HBV) [92] . These observations can imply the hypothesis in which WNV also have dispersed across countries in the region, affecting localities (countries) adjacent to infected areas. The argument is further strengthened if we consider the transmission routes of HIV, HBV, and WNV. The transmission of HIV and HBV depends on effective human-to-human contacts, which acts as a barrier for virus dispersion over large geographic distances. However, similar to other arboviruses like Dengue and Crimean-Congo Hemorrhagic Fever [93, 94] , the cross-country spread of WNV can be much easier and fast as it can be transmitted through a broad range of vectors and reservoirs.
Most of the seroepidemiological studies included in this review used ELISA for the detection of anti-WNV antibodies. Although this assay is simple, sensitive, and commercially available, it suffers from cross-reactivity with antibodies raised against other flaviviruses. So, using the ELISA method for testing individuals with a history of vaccination against, or infection with related flaviviruses can yield false positive results [95] . To achieve a more specific measurement, positive ELISA test results should be confirmed by the plaque reduction neutralization test (PRNT), which is considered as the gold standard method for WNV serological testing. However, PRNT can detect antibodies at levels that neutralize the virus; therefore, it has low sensitivity for seroepidemiological studies in weakly-exposed populations [95] .
Approximately, one-fifth of WNV infected individuals demonstrate symptomatic infection [96] . Clinical symptoms are also non-specific to the disease and include fever, malaise, headache, back pain, myalgia, and anorexia. Therefore, WNV infected individuals can be misdiagnosed with other febrile infections. In areas with evidence of WNV circulation, WNV infection should be considered as a differential diagnosis for patients demonstrating non-differential febrile syndroms.
Non-specific sympotoms of the WNV infection also highlights the need for laboratory testing of suspected human cases. While WNV IgM is the most common target for confirmation of the infection, viral RNA testing can also be performed. Combining IgM detection and viral RNA testing can enhance the possibility of diagnosis in patints with West Nile fever, as indicated by Tilley et al. [97] . However, among 15 studies on patient populations, only four used a combination of serological and molecular assays for the diagnosis of WNV infection.
In this review, we have highlighted serological evidence of WNV infection from 22 independent studies conducted on animal populations in the region. These studies were carried out in 10 countries including, Djibouti, Iran, Jordan, Morocco, Pakistan, Palestine, Qatar, Saudi Arabia, Tunisia, and the UAE. Most studies, have investigated evidence of WNV infection among domestic animals. Since 2010, the highest prevalence of WNV among domestic animals, has been reported among dogs of Morocco and equids of Morocco, Pakistan, Palestine and Iran. The high rates of animal seropositivity and geographic distribution of animal infection reflect the favorable conditions for the circulation of WNV in these countries. In these areas, stronger preventive measures should be considered to reduce the risk of WNV transmission to humans and horses. High seropositivity among dogs and equids also suggests that these animals can be useful sentinels for WNV surveillance, as discussed by previous studies [98] [99] [100] . Resnick, et al. (2008) reported that WNV seroconversion in dogs happened six weeks prior to the infection in exposed human cases [100] .
Only two studies from Pakistan (on rodents) [45] and Djibouti (on wild ruminants) [66] ) have investigated wild animals' infection with WNV. The paucity of published studies on the prevalence of WNV infection in wild animals of the EMRO region underlines a gap in current knowledge about the issue. Knowledge about the reservoirs' infection and virus circulation among wild animals has important implications for forecasting the emergence or re-emergence of WNV epidemics [95] . So, it is recommended future seroprevalence studies include representative samples from wild animals to further illuminate the state of the infection among these hosts.
Four studies investigated the infection among birds from Iran, Morocco, and Tunisia, from which only two studies were recently performed (i.e., Tunisia, 2015 and 2017). These observations also highlight a gap in current knowledge, this time, on the extend of the infection among birds of the EMRO region. Birds play a critical role in the maintenance and spread of the virus. Prolonged high levels of viremia have been demonstrated in several bird species [101, 102] . The virus has also been isolated from several migratory birds. Thus, surveillance of WNV infection among birds would be of great importance, especially in areas with favorable ecological conditions for birds and mosquitoes. In this regards, a better understanding of birds migration routes would be helpful in selecting the most probable sites for tracking the virus [102] , and subsequently making judgments on what areas might be focal points for the emergence of WNV outbreaks.
Mosquitoes and birds are currently considered to have the key role in the life cycle of the virus [2] . However, there are more than 30 other vertebrates such as lemurs, frogs, hamsters, squirrels, rabbits, and chipmunks that have been reported as possible reservoirs for the virus, since they can provide viremia levels that are sufficient to infect mosquito vectors [103] . The role of these reservoirs in the WNV life cycle and epidemic has been less regarded till now, and is an open area for future research.
Despite the critical role of the vector in the life cycle and the epidemic of WNV, only nine studies have investigated vector infection in the region. These studies have been conducted in Djibouti, Egypt, Iran, Pakistan, and Tunisia. The primary vector of WNV, i.e., Cx. pipiens s.l. [2] was detected in all investigared countries except Pakistan. Although WNV infection has been detected in more than 60 mosquito species, detection of viral infection in a mosquito alone does not indicate that the mosquito is a competent vector for the virus. In addition to Culex species, WNV has also been detected in Aedes and Mansonia mosquitoes. Additional studies are necessary to further clarify the potential role these species in the maintenance and transmission of WNV. Interestingly, WNV infection was observed in ticks Argas reflexus hermannii. Previous studies from other regions of WHO also detected WNV RNA in ticks R. turanicus and mites D. gallinae and O. sylvarum. However, their competency as vectors is less clear [104] . Reducing virus transmission from a vector is one of the main strategies of controlling arboviral diseases. Therefore, more efforts to identify the main vectors and understand virus-vector interaction in burdened countries would benefit disease control strategies [105] .
The main limitations of this systematic review relate to the data. First, there is a paucity of prevalence studies in the EMRO region, and the quality of data reported by studies varied. For instance, many available studies on human populations were focused on adults, or did not report age and gender for the study sample. The remaining studies included a broad range of age groups (including infant, children, and adults), most of which did not report age and gender specific prevalence. Prevalence data on healthy infants and young children alone was particularly sparse. Therefore, the state of the epidemic among different age and sex groups remains unknown in this region and requires further study with representative samples. Although current data provides a good basis for an overall judgment about the presence of current/past WNV exposure in most investigated samples, they can hardly be used to infer the actual prevalence and state of the epidemic in most investigated countries. For example, only in four countries with available data on the 'general population' (i.e., Egypt, Iran, Lebanon, and Pakistan), the total number of tested individuals was reasonably representative of the target population (i.e., more than 1000). These 'powerful' studies, however, were not totally flawless. One of the main limitations of these studies was that some of them had used convenience (non-random) sampling methods. In convenience sampling, individuals have unequal and unknown probability of being selected [106] . Hence, the resulting seroprevalence estimates should be generalized to the target population with caution. Few studies available from animal populations in the region also suffered from the abovementioned shortcomings; i.e., non-random sampling and small sample sizes. For example, the seroprevalence of WNV has been investigated in Morocco, Palestine, and Tunisia, but only the study in Morocco has provided the estimate based on a fairly representative sample of 556 and 836 camels for the years 2003 and 2009, respectively. The case was even worse for the seroprevalence studies on dogs, cows, sheep, goats, buffalos, and birds as none of the available studies were well-powered enough (i. e., had small sample sizes). The situation was more satisfactory for the population of horses, where a number of studies with large sample sizes were available from different parts of Iran, Morocco, Pakistan, Palestine, Tunisia, and the UAE. Second, the relative dearth of recent seroprevalence studies, particularly from burdened areas for WNV infection and high-risk population groups is a serious limitation. As the face of WNV disease and its geographic range changes rapidly, WNV prevalence estimated by older studies may not properly reflect the current status of WNV circulation. Less accurate serological tests used by older studies also affect the validity and reliability of the prevalence estimates in these studies. Standardized seroprevalence studies at national levels are critical to best appraise the epidemic status, the impact of interventions and the potentials for future outbreaks. Third, substantial within-country heterogeneity in the prevalence of WNV was noted. This might be due to diversity in the geographical areas, target groups, and the reported sample sizes of studies. Local prevalence estimates, hence, might not be representative of national level prevalence, particularly in large countries with much geographic and ethnic disparities. Finally, our review is limited to reports written in English.
Conclusions
This review provides estimates of the scale of the WNV epidemic at country and regional levels in order to inform efforts for developing and implementing effective future responses. Our results suggested the circulation of WNV in humns, animals, or vectors of most investigated countries in the region. However, there is paucity of data about WNV infection, especially with respect to the burden of the infection in most countries across the region. Hence, further epidemiological studies that take into account the human, reservoir and vector dimension/ aspect of the occurrence and distribution of the virus should be conducted particularly in high-prevalent countries. Such research effort will generate robust knowledge and a detailed understanding of the epidemiology of the infection in local populations, and foster in-depth investigations about transmission patterns of the virus. Identification of the geographic distribution of primary reservoirs of the virus and their infection status can also enhance targeted prevention and elimination efforts and aid forecasting attempts. Moreover, surveillance capacities in EMRO countries ought to be established or expanded for better monitoring of WNV infection at national and regional levels. 
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